What the FDA labels say about taking them together
Heparin and oritavancin
Oritavancin's FDA label of December 18, 2025 names heparin in its contraindications section; the heparin labels PlainMeds reads (4) do not name oritavancin. The oritavancin label: “CONTRAINDICATIONS Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration. Known hypersensitivity to oritavancin products.”
Check it at the source: the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC); the oritavancin FDA label on DailyMed (effective December 18, 2025, Melinta Therapeutics, LLC).
What does the heparin label say about oritavancin?
Heparin's label (effective November 28, 2025) and its 3 other brand-application labels do not name oritavancin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
What does the oritavancin label say about heparin?
Oritavancin label, contraindicationsCONTRAINDICATIONS Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration. ( 4.1 , 5.1 ) Known hypersensitivity to oritavancin products.
Oritavancin label, drug interactionsIn addition, oritavancin does not affect tests that are used for diagnosis of Heparin Induced Thrombocytopenia (HIT).
Source: FDA drug label (Orbactiv, NDA206334), Melinta Therapeutics, LLC, effective July 17, 2025 (SPL set ff09a726-9f9b-4e30-b509-396781293220), via openFDA
Source: FDA drug label (Kimyrsa), Melinta Therapeutics, LLC, effective December 18, 2025 (SPL set 5e755c40-6e73-4572-b474-4d8a131693d1), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Heparin | Oritavancin | |
|---|---|---|
| Labeled for | Blood clots (DVT and PE), Atrial fibrillation | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $1.18 per mL 5,000 unit/mL vial | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once